Australia's most trusted
source of pharma news
Friday, 06 February 2026
Posted 6 February 2026 AM
New Zealand's Pharmac is looking at funding a new first-line treatment for the rare blood cancer systemic anaplastic large cell lymphoma (sALCL) from the beginning of April.
The move would see Takeda's monoclonal antibody Adcetris become a first treatment option for newly diagnosed sALCL, instead of requiring patients to have a lymphoma that has returned or has not responded to earlier treatment.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.